myr-FLAG-AKT1-pcw107 Citations (4)

Originally described in: Systematic identification of signaling pathways with potential to confer anticancer drug resistance.
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877. PubMed Journal

---

Articles Citing myr-FLAG-AKT1-pcw107

Articles
PRMT5-mediated arginine methylation activates AKT kinase to govern tumorigenesis. Yin S, Liu L, Brobbey C, Palanisamy V, Ball LE, Olsen SK, Ostrowski MC, Gan W. Nat Commun. 2021 Jun 8;12(1):3444. doi: 10.1038/s41467-021-23833-2. PubMed
FOXO nuclear shuttling dynamics are stimulus-dependent and correspond with cell fate. Lasick KA, Jose E, Samayoa AM, Shanks L, Pond KW, Thorne CA, Paek AL. Mol Biol Cell. 2023 Mar 1;34(3):ar21. doi: 10.1091/mbc.E22-05-0193. Epub 2023 Feb 3. PubMed
LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinase. Ferrarone JR, Thomas J, Unni AM, Zheng Y, Nagiec MJ, Gardner EE, Mashadova O, Li K, Koundouros N, Montalbano A, Mustafa M, Cantley LC, Blenis J, Sanjana NE, Varmus H. bioRxiv [Preprint]. 2023 Oct 20:2023.10.19.563158. doi: 10.1101/2023.10.19.563158. PubMed
Genome-wide CRISPR screens in spheroid culture reveal that the tumor suppressor LKB1 inhibits growth via the PIKFYVE lipid kinase. Ferrarone JR, Thomas J, Unni AM, Zheng Y, Nagiec MJ, Gardner EE, Mashadova O, Li K, Koundouros N, Montalbano A, Mustafa M, Cantley LC, Blenis J, Sanjana NE, Varmus H. Proc Natl Acad Sci U S A. 2024 May 21;121(21):e2403685121. doi: 10.1073/pnas.2403685121. Epub 2024 May 14. PubMed

If you have published an article using this material, please email us at to have your article added to this page.